EMA accepts Biogen, AbbVie's MS application; Shire teams up for rare disease R&D;

@FierceBiotech: EuroBiotech Report: Billionaires drive Malin to €330M IPO, Push for EU JOBS Act, RNAi stock jumps on PhIIa data. Read more | Follow @FierceBiotech

@JohnCFierce: ICYMI: Not giving up day job, but interviewing @Asthika from Bloomberg Intelligence on biotech market was fun. Watch | Follow @JohnCFierce

@DamianFierce: Early contender for next year's #FierceMadness: $LLY and Boehringer say Jardiance + metformin = Synjardy. | Follow @DamianFierce

> The European Medicines Agency has accepted Biogen ($BIIB) and AbbVie's ($ABBV) application for daclizumab, a once-a-month treatment for multiple sclerosis. More

> Novo Nordisk ($NVO) is launching Novoeight, a new factor-replacement therapy for hemophilia A. News

> Shire ($SHPG) is pairing up with the Cincinnati Children's Hospital Medical Center to discover and develop new treatments for rare diseases in a three-year partnership. Release

Medical Device News

@FierceMedDev: Olympus releases updated endoscope cleaning instructions amid pushback. Story | Follow @FierceMedDev

@EmilyWFierce: ICYMI from FiercePharma: Dr. Reddy's shopping for deals up to $1B as it expands in injectable meds. Report | Follow @EmilyWFierce

> Google, J&J partner to advance surgical robotics. More

> Premier CEO says hospitals must integrate their supply chain to track spending on medical devices. Article

Pharma News

@FiercePharma: Jaguar Animal Health eyes a second run at IPO. Story from FierceAnimalHealth | Follow @FiercePharma

@EricPFierce: IPCA says FDA bans will have little sales impact. Didn't Wockhardt make that claim before its profits sank? FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Hey, European countries--join forces to bring down drug prices, WHO suggests. Article | Follow @CarlyHFierce

> Genentech project to add 100 jobs. News

> Orexigen's Mysimba catches up to Saxenda at EMA finish line. Article

Suggested Articles

Gilead Chief Scientific Officer and R&D chief John McHutchison, M.D., is leaving one year after he replaced R&D lead Norbert Bischofberger, Ph.D.

Astellas will develop Frequency's hearing loss drug outside the U.S. in exchange for $80 million upfront and the promise of $545 million down the line.

Inovio Pharmaceuticals is cutting 28% of its workforce and swinging the ax to a bladder cancer test.